{"entity":{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","aka":[],"tldr":"Leads Dana-Farber's breast oncology division and many of the trials that moved ADCs and de-escalated therapy into breast cancer care.","summary":"Sara M. Tolaney is Chief of the Division of Breast Oncology and Associate Director of the Susan F. Smith Center for Women's Cancers at Dana-Farber Brigham Cancer Center. She is known for leading the APT trial that established adjuvant paclitaxel and trastuzumab for small HER2-positive tumours, and for many of the trials that moved antibody-drug conjugates and de-escalated therapy into breast cancer care, as a principal investigator across the DESTINY, TROPION and HER2CLIMB programmes and trials of sacituzumab govitecan in triple-negative disease. Her selected papers report adjuvant paclitaxel and trastuzumab for node-negative HER2-positive breast cancer, and TROPION-Breast01 comparing datopotamab deruxtecan with chemotherapy in hormone receptor-positive, HER2-negative breast cancer.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/sara-m-tolaney"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tolaney%20SM%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","tnbc"],"sections":[],"technologies":["adc"],"targets":["her2","trop2"],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan","sacituzumab-govitecan","trastuzumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["apt-trial","tropion-breast01","destiny-breast09"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Division of Breast Oncology; Associate Director, Susan F. Smith Center for Women's Cancers","institutionId":"dana-farber","specialisms":["Breast cancer","HER2-positive breast cancer","Antibody-drug conjugates","De-escalation"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/sara-m-tolaney"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tolaney%20SM%5BAuthor%5D"}],"papers":[{"title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","journal":"New England Journal of Medicine","year":2015,"url":"https://doi.org/10.1056/NEJMoa1406281","doi":"10.1056/NEJMoa1406281"},{"title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer (TROPION-Breast01)","journal":"Journal of Clinical Oncology","year":2025,"url":"https://doi.org/10.1200/JCO.24.00920","doi":"10.1200/JCO.24.00920"},{"title":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2028485","doi":"10.1056/NEJMoa2028485"},{"title":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","journal":"Journal of Clinical Oncology","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=monarchE+abemaciclib+adjuvant+Johnston+2020"}]},"route":"/people/sara-tolaney/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"}],"trial":[{"id":"apt-trial","kind":"trial","name":"APT (adjuvant paclitaxel-trastuzumab)","route":"/trials/apt-trial/"},{"id":"atempt","kind":"trial","name":"ATEMPT","route":"/trials/atempt/"},{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/"},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"paper":[{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/"},{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/"},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/"},{"id":"paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013","kind":"paper","name":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","route":"/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/"},{"id":"paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020","kind":"paper","name":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","route":"/key-papers/paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020/"},{"id":"paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020","kind":"paper","name":"Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer","route":"/key-papers/paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020/"}]}}